Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer

Novel inhibitors are urgently needed for use as targeted therapies to improve the overall survival (OS) of patients with ovarian cancer. Here, we show that cell division cycle 25B (CDC25B) is over-expressed in ovarian tumors and associated with poor patient prognosis. All previously reported CDC25B...

Full description

Bibliographic Details
Published in:Frontiers in Oncology
Main Authors: Yangjiong Xiao, Yang Yu, Dan Gao, Wangrui Jin, Pengcheng Jiang, Yuhong Li, Chao Wang, Yuning Song, Peng Zhan, Fei Gu, Cancan Zhang, Bin Wang, Yihua Chen, Bing Du, Rong Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-04-01
Subjects:
WG-391D
ovarian cancer
PDX
primary cell lines
target therapy
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00236/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00236/full

Similar Items